MOTS-c dosage: what the studies used
There is no established MOTS-c dosage for humans. The FDA's 2026 review found no clinical studies and no human exposure data for MOTS-c.1 The doses that have been published come from mouse and rat studies, mostly 5 or 15 mg per kg of body weight once a day.1, 2 This page reports those studies, the one human trial now running, and the arithmetic for a vial.
Important. MOTS-c is not an FDA-approved medicine. FDA staff found no data to support its safety or effectiveness in humans and raised a concern about immune reactions to injected MOTS-c.1 This page reports what studies tested. It does not recommend using MOTS-c or any dose of it, and nothing here is medical advice.
MOTS-c units calculator
Result
- Volume
- Concentration
- Doses per vial
How this was worked out
The same dose with other amounts of water
| Water | mg/mL | Units |
|---|
Arithmetic for comparison only, not a suggestion to change your mix. More water means more units for the same dose.
This is arithmetic on the numbers you entered. It does not tell you what dose to take. Confirm with your prescriber or pharmacist.
Want to save this vial and get dose reminders? Get early access
The 5 mg and 10 mg buttons are the vial sizes named in the nomination the FDA reviewed.1 The calculator converts numbers you enter. It does not suggest a dose.
MOTS-c dosage at a glance
- Approved human dose: none. MOTS-c is not an approved medicine.1
- Human studies with results: none found by the FDA in 2026.1
- Doses in animal studies: 0.5 to 15 mg per kg of body weight, by injection into the abdomen.1, 2
- Schedules in animal studies: mostly once a day, and three times a week in one study of old mice.1, 2
- Human trial running: one Phase 2a trial, a fixed dose once a day for 12 weeks. The amount is not published.4
- Vial sizes named to the FDA: 5 mg and 10 mg of freeze-dried powder, for injection under the skin, with no dosing schedule given.1
- Side effects: unknown in humans. The FDA found no human safety data.1
- Sport: banned at all times by the World Anti-Doping Agency.8
What is MOTS-c?
MOTS-c is a small peptide made of 16 amino acids. Its instructions sit in the DNA of the mitochondria, the parts of a cell that produce energy, inside a gene called 12S rRNA.1 The body makes it naturally, and it is found in human blood.1
Exercise raises the body's own level. In a study of 10 healthy young men, one session of hard interval cycling raised MOTS-c about 12-fold in muscle and about 1.6-fold in blood, and the blood level was back to normal after four hours of rest.2 No one in that study was given MOTS-c.2
The uses put to the FDA were insulin resistance, obesity, osteoporosis, hardening of blood vessels, muscle and fat metabolism, and longevity.1 The FDA's reviewers wrote that the molecule MOTS-c acts on in the body has not been identified.1
How MOTS-c works
The short answer is that nobody is sure. Here is what cell and mouse studies suggest, and where the gaps are:
- It switches on AMPK. AMPK is a sensor inside cells that responds when energy runs low. The animal findings depend at least partly on it.1
- The proposed route to AMPK is indirect. In cell experiments, MOTS-c slowed a chain of reactions called the folate cycle. That let a natural compound called AICAR build up, and AICAR activates AMPK.13, 14 The FDA describes this as the researchers' proposed chain, taken from cell work.1
- It moves into the nucleus under stress. When cells are short of sugar or under oxidative stress, MOTS-c travels to the nucleus and attaches to proteins that control stress-response genes.14, 13
- No receptor has been found. A 2022 review states that no cell receptor for MOTS-c has been identified.13
- The FDA's conclusion: the molecular target is unknown, which makes it hard to predict which organs an injected dose might affect.1
A 2023 review adds that it is still unclear how MOTS-c gets into cells without being broken down first.15
The body's own MOTS-c levels
Most human research on MOTS-c measures the amount people make naturally. None of these studies gave anyone MOTS-c.
| Group | Finding |
|---|---|
| 10 young men, hard exercise | About 1.6 times higher in blood during exercise, normal again after 4 hours |
| 225 adults in Qatar | About 27% lower in poorly controlled type 2 diabetes than in healthy adults |
| Same study, well-controlled diabetes | No significant difference from healthy adults |
| Obese boys and teenagers in China | About 20% lower than in peers |
| Older and younger adults | Reviews report lower blood levels with age, but studies conflict |
The exercise figures come from the 2021 study.2 The diabetes figures come from a 2019 study, whose authors note that both groups were overweight and the healthy group was younger, so the cause is unclear.12 The other rows come from review articles, which also report that findings differ by sex, ethnicity and stage of disease.15, 14
More findings from the same sources:
- Diabetes medicines made no difference. In the Qatar study, people taking metformin or insulin had similar MOTS-c levels to those who were not.12
- A gene variant. A variant of the MOTS-c gene found in Asian populations has been linked to a higher risk of type 2 diabetes in men.13
- Sex differences. Lower levels were seen in obese boys but not in obese girls.14
- Kidney disease. Lower levels have been reported in chronic kidney disease.14
- Not every exercise study agrees. In one study, endurance exercise did not change blood levels.14
A lower natural level in a group of people does not show that injecting MOTS-c would help them. That question needs a trial, and the first one is still running.4
Is there a recommended MOTS-c dosage?
No. An official dose comes from human trials and an approved label, and MOTS-c has neither. Here is what the FDA's review found:1
- No clinical studies of MOTS-c in humans.
- No human exposure data and no data on how the human body absorbs or clears it.
- No reports in the FDA's database of side-effect reports.
- The nomination proposed 5 mg and 10 mg vials for injection under the skin, and gave no dosing schedule and no amount of liquid for mixing.
So the numbers below are doses that researchers gave to animals, and one schedule from a human trial that has not reported. They are evidence about what was studied. They are not doses for a person.
MOTS-c doses in animal studies
These are the dosing studies described in the FDA's review, plus details we read in the full text of the 2021 study. Every one gave MOTS-c by injection into the abdomen, a route used in laboratory animals.1, 2
| Study | Dose | Schedule |
|---|---|---|
| Lee 2015, mice | 0.5 mg/kg | Daily, 8 weeks |
| Lee 2015, mice | 5 mg/kg | Daily, 7 days |
| Kim 2019, mice | 2.5 mg/kg | Twice daily, 3 days |
| Lu 2019, mice | 5 mg/kg | Daily, 12 weeks |
| Reynolds 2021, mice | 5 or 15 mg/kg | Daily, 10 days |
| Reynolds 2021, old mice | 15 mg/kg | Daily, 2 weeks |
| Reynolds 2021, old mice | 15 mg/kg | 3 times a week |
| Wei 2020, rats | 5 mg/kg | Daily, 4 weeks |
What each study reported:
- Lee 2015, 0.5 mg/kg: mice on a high-fat diet gained about 20% less weight than untreated mice and had less fat in the liver.1
- Lee 2015, 5 mg/kg: in 12-month-old mice, muscle responded to insulin as it did in 3-month-old mice.1
- Kim 2019: blood sugar fell by about half in obese mice.1
- Lu 2019: female mice without ovaries gained less weight and fat.1
- Reynolds 2021, young mice: only the 15 mg/kg group ran significantly better on a treadmill. The 5 mg/kg group did not.2
- Reynolds 2021, old mice, daily: treated 22-month-old mice ran about twice as long as untreated ones.2
- Reynolds 2021, old mice, three times a week: grip strength and walking improved. Median lifespan was 6.4% longer, but the difference was not statistically significant, and the authors asked for larger studies.2
- Wei 2020: rats had less calcium build-up in the main artery.1
The FDA's reviewers noted two limits. The studies did not test how the effect changes with dose, and there are no standard animal safety studies: none on repeated dosing, reproduction, genetic damage or cancer.1
MOTS-c benefits by level of evidence
Every claimed benefit rests on animal or cell studies. This table shows the best evidence for each and whether any human test exists.
| Claim | Evidence | Humans |
|---|---|---|
| Blood sugar, insulin | Mice | Trial running |
| Weight, body fat | Mice | No |
| Exercise capacity | Mice | No |
| Ageing, lifespan | Old mice | No |
| Bone strength | Mice and cells | No |
| Blood vessels | Rats | No |
| Pain, swelling | Mice | No |
| Memory | Mice | No |
- Blood sugar, weight and exercise: see the studies above.1, 2 The running human trial measures insulin sensitivity.4
- Lifespan: the one mouse study found a 6.4% longer median lifespan that was not statistically significant.2
- Bone: studies in mice without ovaries and in bone cells, described in a 2022 review as preclinical only.13
- Blood vessels: less calcium build-up in rat arteries.1 In people, one observational study linked lower natural levels to poorer function of the heart's arteries.13
- Inflammation and pain: a mouse pain test.15
- Memory: mouse studies in which MOTS-c had to be joined to a carrier molecule to cross from blood into the brain.14
The 2022 review sums up the position: nearly all the therapeutic evidence is preclinical, and human data are limited to observed associations.13
MOTS-c dosage by goal: what was actually tested
Many guides give a different dose for each goal. No study supports that for people. Here is what was tested for each goal, all in animals:
Weight loss
Mice fed a high-fat diet received 0.5 mg per kg a day for eight weeks and gained about 20% less weight than untreated mice. Female mice without ovaries received 5 mg per kg a day for 12 weeks and gained less weight and fat.1 No human weight-loss study exists.
Blood sugar and insulin resistance
Obese mice received 2.5 mg per kg twice a day for three days, and their blood sugar fell by about half. Older mice received 5 mg per kg a day for a week, and their muscle responded to insulin like that of young mice.1 This is the goal of the one human trial, which has not reported.4
Exercise and endurance
Young mice ran significantly better only at 15 mg per kg a day, and not at 5 mg per kg. Old mice on 15 mg per kg a day for two weeks ran about twice as long as untreated ones.2 No human performance study exists, and MOTS-c is banned in sport.8
Longevity
Old mice received 15 mg per kg three times a week from late life. Their median lifespan was 6.4% longer, a difference that was not statistically significant.2
So the only dose comparison in the published work is one mouse experiment, in which the higher of two doses worked and the lower did not.2
MOTS-c dosage per day and per week
Searches for a "per day" or "per week" MOTS-c dose have no human answer. What exists is this:
| Where | Per day | Per week |
|---|---|---|
| Mice and rats | 0.5 to 15 mg/kg | Mostly daily |
| Old mice, 2021 | 15 mg/kg | 3 days a week |
| Human trial | Fixed, not stated | Daily, 12 weeks |
| Approved label | None | None |
The mouse figures are in mg per kg of the animal's body weight.1, 2 The human trial row comes from its registry entry.4
Why a mouse dose is not a human dose
- The route differs. The animals were injected into the abdomen. The proposal put to the FDA was injection under the skin.1
- Body size does not scale in a straight line. Multiplying a mouse's mg per kg by a person's weight is not how researchers set a first human dose, and this page does not attempt a conversion.
- MOTS-c breaks down fast in blood. In a laboratory test, MOTS-c added to human blood was quickly cut into smaller pieces within 15 to 60 minutes. The FDA wrote that it is still unknown whether an injected dose can reach an active level in people.1
- Nobody tested a range. The animal studies did not map dose against effect.1
Human trials of MOTS-c
MOTS-MET, the first registered trial
One trial of MOTS-c itself is registered. It has no results yet.4 The FDA's review, dated May 2026, does not mention it.1
- Who: an estimated 120 adults with prediabetes and overweight or obesity.
- Design: Phase 2a, randomised, double-blind, MOTS-c against placebo.
- Dose: a fixed dose injected under the skin once a day for 12 weeks. The registry entry does not state the amount.
- Measured: change in insulin sensitivity at 12 weeks, and side effects through week 16.
- Where and when: Peking University Shenzhen Hospital in China. It started in February 2026, and its estimated date for the main measurement is February 2027.
- Sponsor: Hudson Biotech.
CB4211, a related peptide
CB4211 is a modified version of MOTS-c made by a company called CohBar. It is a different molecule, so its dose says nothing direct about MOTS-c. It is the closest human data there is.3
- First stage: single and repeated rising doses for one week in 65 healthy adults.
- Second stage: 25 mg injected under the skin once a day for four weeks, in 20 adults with obesity and fatty liver. Eleven received CB4211 and nine received placebo.
- Reported: the liver enzyme ALT fell 21% on CB4211 and rose 4% on placebo. Blood sugar fell 6% against no change. Liver fat fell by about the same amount in both groups.
- Side effects: no serious ones. Injection-site reactions were the only side effect in more than 1 in 10 people on CB4211.
These figures come from a company press release in August 2021, described as topline results. The trial's main aim was safety, and the other measures were exploratory.3
MOTS-c compared with CB4211, AICAR and the body's own supply
| What | What it is, and its human data |
|---|---|
| MOTS-c, injected | A copy of the natural peptide made in a laboratory. No human dosing data published. |
| The body's own MOTS-c | Made naturally, and rises with hard exercise. Measured in people, never dosed. |
| CB4211 | A modified version from one company. Tested at 25 mg a day for 4 weeks in 20 people. |
| AICAR | A natural compound that activates AMPK. Not covered on this page. |
MOTS-c is thought to act partly by letting AICAR build up inside cells.13, 14 The CB4211 figures are from the company's release.3
MOTS-c and MOTS-c acetate
Vials are sold as MOTS-c or as MOTS-c acetate. The FDA treats these as two different substances that share the same active part.1
- Weight of the molecule: 2,174.6 grams per mole for plain MOTS-c and 2,234.64 for the acetate form.1
- The nomination was unclear about which one it meant. Its description matched plain MOTS-c, and its quality certificate was for the acetate. The FDA reviewed both.1
- The advisory committee also considered each form.16
The calculator on this page works from the milligrams printed on a label. It cannot tell which form a vial holds.
Reconstitution math for a MOTS-c vial
The concentration of a mixed vial is the amount of powder divided by the water added. The table uses the two vial sizes named to the FDA.1 No source gives an amount of water for MOTS-c, and the nomination gave none.1
| Vial | 1 mL | 2 mL | 3 mL |
|---|---|---|---|
| 5 mg | 5 | 2.5 | 1.67 |
| 10 mg | 10 | 5 | 3.33 |
| Vial | 1 mL | 2 mL | 3 mL |
|---|---|---|---|
| 5 mg | 20 | 40 | 60 |
| 10 mg | 10 | 20 | 30 |
| Vial | 1 mL | 2 mL | 3 mL |
|---|---|---|---|
| 5 mg | 0.5 | 0.25 | 0.17 |
| 10 mg | 1 | 0.5 | 0.33 |
For example, by arithmetic, a 10 mg vial with 2 mL of water is 5 mg/mL, so 1 mg is 20 units. That is an illustration, not a recommendation. For the steps, see how to reconstitute peptides, and for the choice of water amount, how much BAC water to add.
A worked example
The same three steps work for any vial. Here they are for a 10 mg vial mixed with 2 mL of water, using 1 mg only as a round number for the arithmetic:
- Concentration: 10 mg ÷ 2 mL = 5 mg/mL.
- Volume: 1 mg ÷ 5 mg/mL = 0.2 mL.
- Units: 0.2 mL × 100 = 20 units on a U-100 syringe.
If an amount is written in micrograms, divide it by 1,000 first to get milligrams. The calculator at the top does all of this and shows its working. How the calculator math works has the formulas and test cases.
A hospital guide for patients who mix an injectable medicine at home says to roll the vial gently and not shake it.11
Injection hygiene: what health guidance says
There are no official instructions for injecting MOTS-c, because there is no approved product. The proposal put to the FDA was injection under the skin.1 The points below are general injection-safety practices written for healthcare settings.17, 10
- Clean hands first, with soap and water or an alcohol rub.17
- Wipe the vial stopper with 70% alcohol and let it air dry before every entry.17
- Use a new sterile syringe and needle every time, including for mixing. Changing only the needle does not make a syringe safe to reuse.17
- Clean the skin with a 60 to 70% alcohol swab, wiping from the centre outward, and let it dry fully.17
- Never leave a needle in the vial between uses.17, 10
- Do not recap, bend or break a used needle. Put it straight into a puncture-proof sharps container, and replace the container when it is three-quarters full.17
How long does MOTS-c stay in the body?
No human measurement exists. The FDA found no data on how the body absorbs or clears MOTS-c, in animals or in people.1 Three findings give partial clues:
- In a test tube, MOTS-c added to human blood at body temperature was cut into shorter pieces within 15 to 60 minutes.1
- After exercise, the body's own blood level was back to normal within four hours.2
- Inside cells, MOTS-c that moved into the nucleus under stress returned within 24 hours.14
None of these is a half-life for an injected dose, and this page does not give one.
Timing: is there a best time to take MOTS-c?
No study has compared times of day, fasting or timing around exercise in humans, because no human study has reported.1 Two facts explain why the question comes up:
- The body's own MOTS-c rises during hard exercise and settles within hours.2
- In the mouse studies, MOTS-c was given daily and running was tested after one to two weeks.2
Neither fact sets a time of day for a person.
Stacking MOTS-c with other peptides
None of the studies we read gave MOTS-c together with another peptide, so there is no evidence about any combination.1, 2 Under the US interim compounding policy, a compounded product may contain only one of the listed peptides.6 This page does not describe stack schedules, because none has a source.
What the studies measured
Guides often list things to track. The studies give a sourced version of that list:
- Insulin sensitivity from a glucose tolerance test, the main measure in the human trial.4
- Liver enzymes, blood sugar and liver fat, in the CB4211 trial.3
- Body weight and fat, in the mouse studies.1
- Running time, grip strength and walking, in the old-mouse study.2
- Side effects, in both human trials.4, 3
Blood tests like these are ordered and read by a clinician. For any vial, keep three numbers written on it: the amount on the label, the water added and the date it was mixed. Without them the concentration cannot be worked out.
MOTS-c side effects and safety
| Question | What is known |
|---|---|
| Side effects in human studies | None recorded, because no human study has reported |
| Reports to the FDA | None found in its side-effect database |
| Immune reaction | A concern the FDA says cannot be ruled out |
| Injection-site reactions | Common with the related peptide CB4211 |
| Repeated dosing in animals | No safety study |
| Pregnancy and fertility | No study |
| Cancer and genetic damage | No study |
| Long-term use | Unknown |
The table draws on the FDA's review and the CB4211 release.1, 3 In more detail:
- Why injection under the skin matters. The FDA notes that this route is generally more likely to provoke an immune response than injection into a vein, and that antibodies could in theory blunt the body's own MOTS-c.1
- No human safety data. The FDA found none for any route.1
- Immune reactions. The FDA is concerned that injected MOTS-c could provoke an immune response, because peptides can clump together and can carry peptide impurities. It wrote that there is not enough data to rule this out.1
- Quality of the raw material. The quality certificates the FDA reviewed lacked limits for impurities and results for clumping, bacteria and endotoxins. One certificate showed 99.2% purity, but the FDA's point is that a purity figure alone does not show what the remaining impurities are.1
- Likely impurities. The FDA expects shortened or incomplete copies of the peptide, plus leftover solvents and chemicals from manufacture.1
- No standard animal safety studies. None on repeated dosing, reproduction, genetic damage or cancer.1
- The related peptide. In the CB4211 trial, injection-site reactions were the common side effect over four weeks.3
- Long-term use. The longest animal study in the FDA review ran 12 weeks, apart from the late-life mouse study.1, 2
The FDA's four tests
The FDA judges a substance for compounding on four points. For MOTS-c its staff concluded:1
- Is the substance well described? No. Both forms were judged not well characterised.
- Is there a history of use in compounding? Unknown. No published human use, and no reports of it being compounded between January 2017 and December 2025. It is marketed online.
- Is it safe? Unknown. Only rodent studies of its effects exist, with no safety studies and no human data.
- Does it work? Unknown. There are no clinical studies, and it is not known whether the rodent findings carry over to people.
Storage and refrigeration
There is no approved label, so there are no official storage instructions. Here is what the sources say:
- Supplier figures are not tested figures. The FDA review records supplier claims that the powder is stable frozen at -20°C and that a mixed solution keeps 2 to 7 days in a fridge. It notes these come from supplier websites, not studies.1
- Peptides are fragile. The FDA stresses that they are sensitive to temperature, acidity and concentration, and may clump.1
- The water's own label says not to store mixed solutions unless the maker of the drug directs otherwise.9
- The general rule for multi-dose vials in healthcare settings is to date them when opened and discard within 28 days unless the manufacturer says otherwise.10 That is an infection-control rule. It is not a tested shelf life for mixed MOTS-c.
We do not give a number of days, because no source has tested one. See also how to store BAC water.
Legal status in the United States
- Not approved. MOTS-c is not an FDA-approved medicine.1
- History of use: MOTS-c was discovered in 2015. The FDA found no published human use and could not tell how long or how widely it has been compounded.1
- FDA staff, May 2026: proposed not adding MOTS-c to the list of substances that pharmacies may compound from, citing the lack of human and safety data.1
- Advisory committee, 23 July 2026: voted 7 to 5, with 2 abstentions, to recommend adding it. The uses on its agenda were obesity and osteoporosis.16 The vote does not bind the FDA.7
- Interim federal policy, 30 October 2026: the Department of Health and Human Services said it does not intend to act against pharmacies and doctors who compound certain peptides while the list is settled by rulemaking. It does not add anything to the list, it is not an approval, and the department may revisit it if a safety or quality problem appears.5
- Conditions of that policy: for MOTS-c it covers injections under the skin or into muscle, a single listed peptide per product, a patient-specific prescription and a certificate of analysis for the raw material. No dose is set.6
- The policy's own caution: compounded drugs are not FDA-approved, so the FDA does not check their safety, effectiveness or quality before they are sold.5
This is a summary of public documents as of 2026-11-20, not legal advice. The rules are changing.
What the interim policy asks of a pharmacy
For anyone prescribed compounded MOTS-c in the United States, a law firm's summary of the policy lists these conditions. They are useful questions to put to a pharmacy:6
- Is there a prescription for a named patient? The policy requires one.
- Where did the raw material come from? It must come from an FDA-registered facility, with a certificate of analysis covering identity, purity, strength and contaminants.
- Is it a single peptide? A product may contain only one of the listed peptides.
- Is it an injection? For MOTS-c the policy covers injection under the skin or into muscle only.
- How is it labelled? The label must carry a "not for resale" statement.
- Are problems reported? Serious side effects and quality problems must be reported to the FDA's MedWatch system.
A vial sold online without a prescription does not meet these conditions.
What could change this page
- The first trial result. MOTS-MET lists February 2027 as the estimated date for its main measurement.4
- A final FDA rule on whether MOTS-c joins the compounding list. The interim policy lasts until then.6
- A change to the interim policy, which the department says it may revisit.5
MOTS-c and drug testing in sport
The World Anti-Doping Agency's 2026 Prohibited List names MOTS-c as an example of an AMPK activator under section S4, hormone and metabolic modulators. Substances in that section are prohibited at all times, in and out of competition.8
Terms used on this page
- mg/kg: milligrams of substance for each kilogram of the animal's body weight. It is how animal doses are written.
- Injection into the abdomen: a route used in laboratory animals, written as "intraperitoneal" or IP in the studies.
- Injection under the skin: written as "subcutaneous" or SC.
- AMPK: a sensor inside cells that responds when energy runs low.
- Phase 1, Phase 2a: early stages of human testing. Phase 1 looks mainly at safety. Phase 2a is a first, small test of whether a treatment has an effect.
- Placebo: a dummy treatment that looks the same, used for comparison.
- Topline results: a company's first summary of a trial, before full publication.
- Freeze-dried powder: written as "lyophilized" on vials. It is mixed with liquid before use.
- U-100 syringe: an insulin syringe on which 100 units equal 1 mL.
- Compounding: a pharmacy making a medicine for an individual patient from raw ingredients.
Common mistakes
- Reading a mouse dose as a human dose. The published numbers are mg per kg in animals, by a different route.1
- Mixing up mg and mcg. One milligram is 1,000 micrograms. See mcg to mg.
- Treating units as milligrams. Units measure volume on the syringe. See units are not milligrams.
- Forgetting how much water went in. Without that number the concentration is unknown.
- Trusting a storage time that no one tested. The figures in circulation come from supplier websites.1
Questions
What is the recommended MOTS-c dosage?
There is none. MOTS-c is not an approved medicine, and the FDA review of it found no clinical studies and no human exposure data. No human dose has been established by a published study.
What MOTS-c dosage per day did studies use?
The published dosing studies are in mice and rats, and most gave 5 or 15 mg per kg of body weight once a day by injection into the abdomen. One human trial of MOTS-c is registered with a fixed dose once a day for 12 weeks, but the amount is not published.
What MOTS-c dosage per week is reported?
No weekly human dose is reported. In one mouse study, old mice received 15 mg per kg three times a week. That is a mouse schedule and it does not convert into a human amount.
Is MOTS-c taken daily or weekly?
No human schedule has been established. The mouse studies mostly dosed once a day, and one dosed three times a week. The registered human trial gives its fixed dose once a day.
Has MOTS-c been tested in humans?
No results in humans have been published. The FDA found no clinical studies in its 2026 review. A Phase 2a trial in 120 adults is registered as recruiting in China. A related but different peptide, CB4211, was tested in a small early trial.
How do you reconstitute a 10 mg MOTS-c vial?
No official instruction exists, because there is no approved product. By arithmetic, a 10 mg vial with 1 mL of water makes 10 mg/mL, 2 mL makes 5 mg/mL and 3 mL makes 3.33 mg/mL. The water changes the concentration, not how much MOTS-c is in the vial.
How many units is 1 mg of MOTS-c?
It depends on the mix. For a 10 mg vial with 2 mL of water, 1 mg is 20 units on a U-100 insulin syringe. A different vial size or amount of water gives a different number, so use the calculator with your own numbers.
How long before MOTS-c has an effect?
No one can say for humans, because no human results are published. In mice, the studies reported changes after anything from 3 days to 12 weeks of dosing, depending on what was measured.
Does MOTS-c need to be refrigerated?
There is no approved label, so there are no official storage instructions. The FDA review notes that the storage figures in circulation come from supplier websites and not from studies, and that peptides are sensitive to temperature.
Can MOTS-c be taken orally?
We found no study of MOTS-c taken by mouth. Every animal study in the FDA review gave it by injection, and the current US compounding policy covers injectable forms only for MOTS-c.
Is MOTS-c safe for long-term use?
That is unknown. The FDA found no repeat-dose, reproductive, genetic or cancer safety studies, and no human safety data. It also raised a concern that injected MOTS-c could trigger an immune reaction.
Will MOTS-c cause a positive drug test?
For athletes, MOTS-c is banned. The World Anti-Doping Agency names it on the 2026 Prohibited List as a metabolic modulator, prohibited at all times, in and out of competition.
Is MOTS-c FDA-approved?
No. MOTS-c is not an FDA-approved medicine. FDA staff proposed not adding it to the list of substances pharmacies may compound from. An advisory committee then voted 7 to 5 to recommend adding it, and a federal interim policy from October 2026 allows compounding under conditions while a final rule is written.
Can MOTS-c be stacked with other peptides?
None of the studies we read tested MOTS-c together with another peptide, so there is no evidence about combinations. The US interim compounding policy only covers products that contain a single listed peptide.
How does MOTS-c work?
It is not fully known. In cell and mouse studies MOTS-c switches on an energy sensor called AMPK, and under stress it moves into the cell nucleus and changes which genes are active. No receptor for it has been found, and the FDA wrote that its molecular target is unknown.
What are the side effects of MOTS-c?
No side effects in humans have been recorded, because no human study has reported. The FDA found no reports in its side-effect database and treats the risks as unknown. In the trial of the related peptide CB4211, injection-site reactions were the common side effect.
What is the difference between MOTS-c and MOTS-c acetate?
The FDA treats them as two different substances that share the same active part. The acetate form is slightly heavier, 2,234.64 against 2,174.6 grams per mole. The FDA noted the nomination described one form while its quality certificate was for the other.
Is CB4211 the same as MOTS-c?
No. CB4211 is a modified version of MOTS-c made by a company, and it is a different molecule. Its trial dose of 25 mg a day says nothing direct about MOTS-c.
How long does MOTS-c stay in the body?
No human measurement exists. In a laboratory test, MOTS-c added to human blood was broken into smaller pieces within 15 to 60 minutes. The FDA found no data on how the body absorbs or clears an injected dose, so no half-life can be given.
Does exercise raise MOTS-c naturally?
In one study of 10 young men, a hard cycling session raised MOTS-c about 1.6-fold in blood and about 12-fold in muscle, and blood levels were back to normal four hours later. A review notes another study in which endurance exercise did not change blood levels.
Does MOTS-c help with weight loss?
Only mouse data exists. Mice on a high-fat diet gained less weight when given MOTS-c. No human study has tested weight loss, and the committee that reviewed MOTS-c for obesity had no human results to consider.
Are there MOTS-c before-and-after results?
Not from a study. No human trial of MOTS-c has reported results, so any before-and-after claim is a personal account and not evidence. The first trial lists February 2027 as the estimated date for its main measurement.
What vial sizes does MOTS-c come in?
The nomination the FDA reviewed named 5 mg and 10 mg vials of freeze-dried powder. Other sizes are sold online. The calculator on this page accepts any size.
Has MOTS-c been studied in pregnancy?
No. The FDA found no reproductive or developmental safety studies of MOTS-c, in animals or in people.
Does this guide tell me what dose to take?
No. It reports what the studies used and does the arithmetic for a vial. It does not suggest a dose.
Sources
- U.S. Food and Drug Administration, briefing document for the Pharmacy Compounding Advisory Committee meeting of 23 to 24 July 2026: evaluation of MOTS-c (free base) and MOTS-c acetate for the 503A bulk drug substances list, memo dated 11 May 2026. Our source for the animal studies by Lee (2015), Kim (2019), Lu (2019) and Wei (2020), which we did not open ourselves. fda.gov (PDF) (opens in a new tab)
- Reynolds JC, et al. "MOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline and muscle homeostasis." Nature Communications, 2021;12:470. Mouse experiments, plus measurements in 10 men who were not given MOTS-c. doi.org/10.1038/s41467-020-20790-0 (opens in a new tab)
- CohBar, Inc., press release, 10 August 2021: topline results from the Phase 1a/1b study of CB4211. Company release, not peer-reviewed. CB4211 is an analog of MOTS-c, not MOTS-c. stocktitan.net (copy of the GlobeNewswire release) (opens in a new tab)
- ClinicalTrials.gov, NCT07505745, "MOTS-c for Improving Insulin Sensitivity in Adults With Prediabetes and Overweight/Obesity" (MOTS-MET), sponsor Hudson Biotech, record last updated 1 April 2026, status recruiting. clinicaltrials.gov (opens in a new tab)
- U.S. Department of Health and Human Services, "Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances", notice of availability, Federal Register, 30 October 2026, 91 FR 68526. govinfo.gov (PDF) (opens in a new tab)
- Holland & Knight LLP, "HHS Issues Interim Enforcement Discretion Policy for Compounding of 6 Peptides", November 2026. A law firm's summary of the policy's conditions and appendices, which we could not open in full ourselves. hklaw.com (opens in a new tab)
- American Journal of Managed Care, "FDA Panel Backs 6 Peptides for Compounding", 2026. A news report of the advisory committee votes of 23 to 24 July 2026. ajmc.com (opens in a new tab)
- World Anti-Doping Agency, "World Anti-Doping Code International Standard: Prohibited List 2026", in effect from 1 January 2026, section S4.4.1. wada-ama.org (opens in a new tab)
- Hospira, Inc., Bacteriostatic Water for Injection, USP, prescribing information, revised 11/2019. labeling.pfizer.com (opens in a new tab)
- Centers for Disease Control and Prevention, "Preventing Unsafe Injection Practices", 26 March 2024. Written for healthcare settings. cdc.gov (opens in a new tab)
- St. Jude Children's Research Hospital, "Making liquid medicine for injection", patient education guide. together.stjude.org (opens in a new tab)
- Ramanjaneya M, et al. "Mitochondrial-Derived Peptides Are Down Regulated in Diabetes Subjects." Frontiers in Endocrinology, 2019;10:331. A study of natural levels in 225 adults. No one was given MOTS-c. doi.org/10.3389/fendo.2019.00331 (opens in a new tab)
- Mohtashami Z, et al. "MOTS-c, the Most Recent Mitochondrial Derived Peptide in Human Aging and Age-Related Diseases." International Journal of Molecular Sciences, 2022;23(19):11991. A review article. doi.org/10.3390/ijms231911991 (opens in a new tab)
- Wan W, et al. "Mitochondria-derived peptide MOTS-c: effects and mechanisms related to stress, metabolism and aging." Journal of Translational Medicine, 2023;21:36. A review article. doi.org/10.1186/s12967-023-03885-2 (opens in a new tab)
- Zheng Y, Wei Z, Wang T. "MOTS-c: A promising mitochondrial-derived peptide for therapeutic exploitation." Frontiers in Endocrinology, 2023;14:1120533. A short review article. doi.org/10.3389/fendo.2023.1120533 (opens in a new tab)
- U.S. Food and Drug Administration, "July 23-24, 2026: Meeting of the Pharmacy Compounding Advisory Committee", meeting page with agenda and briefing documents, content current as of 6 August 2026. fda.gov (opens in a new tab)
- World Health Organization, "WHO Best Practices for Injections and Related Procedures Toolkit", chapter 2, 2010. Written for healthcare settings. ncbi.nlm.nih.gov (opens in a new tab)
- Formulas and test cases: how the calculator math works.